Show simple item record

dc.contributor.authorBrusselle, Guy
dc.contributor.authorPrice, David
dc.contributor.authorGruffydd-Jones, Kevin
dc.contributor.authorMiravitlles, Marc
dc.contributor.authorKeininger, Dorothy L
dc.contributor.authorStewart, Rebecca
dc.contributor.authorBaldwin, Michael
dc.contributor.authorJones, Rupert C
dc.date.accessioned2015-12-03T12:02:01Z
dc.date.available2015-12-03T12:02:01Z
dc.date.issued2015
dc.identifier.citationBrusselle , G , Price , D , Gruffydd-Jones , K , Miravitlles , M , Keininger , D L , Stewart , R , Baldwin , M & Jones , R C 2015 , ' The inevitable drift to triple therapy in COPD : an analysis of prescribing pathways in the UK ' , International journal of chronic obstructive pulmonary disease , vol. 10 , no. 1 , pp. 2207-2217 . https://doi.org/10.2147/COPD.S91694en
dc.identifier.issn1176-9106
dc.identifier.otherPURE: 59573222
dc.identifier.otherPURE UUID: 9b42227f-a8e3-4c88-a2dd-d66129ea749d
dc.identifier.otherPubMed: 26527869
dc.identifier.otherScopus: 84944880515
dc.identifier.urihttp://hdl.handle.net/2164/5280
dc.descriptionAcknowledgments The analyses reported in this study were funded by Novartis Pharma AG (Basel, Switzerland) and were conducted by Research in Real-Life Ltd (Cambridge, UK), an independent company. The authors also thank David Bergin, Danielle Corbett, and Vivek Khanna (professional medical writers; Novartis) for assistance in the preparation of this paper. Writing support was funded by Novartis Pharma AG.en
dc.format.extent11
dc.language.isoeng
dc.relation.ispartofInternational journal of chronic obstructive pulmonary diseaseen
dc.rightsThis work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.en
dc.subjectchronic obstructive pulmonary diseaseen
dc.subjectGOLD guidelinesen
dc.subjectobservational studyen
dc.subjectprescribing patternsen
dc.subjectprimary careen
dc.subjectR Medicineen
dc.subject.lccRen
dc.titleThe inevitable drift to triple therapy in COPD : an analysis of prescribing pathways in the UKen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.2147/COPD.S91694


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record